Press Releases
Merck Highlights Data Presentations at the Alzheimer’s Association International Conference, 2012
Merck known as MSD outside the United States and Canada, announced today presentations at the upcoming Alzheimer’s Association International Conference (AAIC) being held in Vancouver,...
Press Releases
Osiris Selected by BARDA to Submit Proposal for the Use of Grafix® in Mass Casualty Thermal Burn Injuries
Osiris Therapeutics, Inc. announced today that the company has been selected by the Biomedical Advanced Research and Development Authority (BARDA) to submit a full...
Press Releases
BioAlliance Pharma extends and strengthens the protection of AMEP® with the grant of two patents in the US
BioAlliance Pharma SA , an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces two key achievements in...
Press Releases
Researcher Discovers Micro RNA Required for the Growth and Spread of Cancer Children’s Hospital Los Angeles
A previously unreported mechanism for the growth and spread of cancer has been reported by Muller Fabbri, MD, first author on the paper that...
Press Releases
Cytheris announces CYT107 orphan drug designation in Europe for the treatment of Progressive Multifocal Leucoencephalopathy (PML)
Cytheris SA, a privately held clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases, announces today that the European Commission has granted an orphan...
Press Releases
Ohio’s Best Rx Card Now Provides Savings to All Ohioans, Regardless of Income Envision Pharmaceutical Services
Ohio’s Best Rx, a free, state-endorsed prescription drug discount program available to seniors and other qualifying low-income families and individuals since 2004, has expanded...
Press Releases
PsiOxus Therapeutics Secures £22 Million in Series B Financing to Drive Clinical Development for Oncolytic Vaccine
PsiOxus Therapeutics, Ltd. announced that it has closed a Series B round of equity financing totaling £22 million ($34 million). ...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.